Modafinil is a wakefulness-promoting drug approved for narcolepsy, sleep apnea and shift-work disorder, used off-label as a cognitive enhancer. A systematic review of 24 placebo-controlled studies found it improves executive function, learning and memory in healthy non-sleep-deprived adults, but effects are modest and largest when users are tired, tasks are hard or baseline performance is low. Dependence risk is low, though it carries a rare Stevens-Johnson risk and reduces the effectiveness of hormonal birth control.
Summary drafted from this entry’s sources; editorial review pending.
01Key questions
Does modafinil make you smarter?
Modestly. A review of 24 placebo-controlled studies found it improves attention, executive function, learning and memory in healthy adults, mainly on demanding tasks or when sleep-deprived; simple tasks and divergent creativity see little or negative effect.1
Is modafinil addictive?
Dependence risk is low. It is Schedule IV, does not reliably produce self-administration in animal models, tolerance generally does not develop at therapeutic doses, and withdrawal is minimal.
Is modafinil legal?
In the US it is prescription-only Schedule IV, approved for narcolepsy, OSA and shift-work disorder. Off-label cognitive use requires a prescription; online gray-market supply is unregulated.
Is modafinil safe?
Common effects are headache, nausea and anxiety; rare but serious is Stevens-Johnson syndrome. It induces CYP3A4, which can reduce the effectiveness of hormonal birth control and other drugs.
What would change this rating?
Long-term safety and outcome data in healthy users, plus positive phase 3 readouts in adjunct indications now being tested such as bipolar cognition.
02Overview
Eugeroics (from Greek eu "good" + gerē "old age/vigilance") are a class of wakefulness-promoting agents that represent arguably the most effective cognitive enhancers currently available. Unlike traditional stimulants (amphetamine, methylphenidate), eugeroics promote alertness and cognitive function through atypical mechanisms — primarily weak, selective dopamine transporter (DAT) inhibition combined with activation of orexin, histamine, and other wakefulness systems.
The flagship eugeroic, modafinil (Provigil®), has been called "the world's first safe smart drug" (Sahakian & Morein-Zamir, 2007) and is used off-label by military pilots, surgeons, students, and executives seeking cognitive enhancement. However, the reality is more nuanced — modafinil is not a magic pill, and its cognitive effects are state-dependent and task-specific.
⚡ Meta-Analysis Finding: A 2019 systematic review and meta-analysis (Battleday & Brem, European Neuropsychopharmacology) found modafinil conferred consistent cognitive benefits in attention, learning, executive function, and memory in non-sleep-deprived adults (PMID 31433334). This was significant because it demonstrated cognitive enhancement beyond mere wakefulness.
03The Eugeroic Family
Modafinil (Provigil®)
| Property | Details |
|---|---|
| Chemical structure | 2-[(diphenylmethyl)sulfinyl]acetamide |
| Form | Racemic mixture of R- and S-enantiomers |
| FDA approval | 1998 (narcolepsy); later OSA, shift-work disorder |
| Legal status | Schedule IV (US); Prescription only |
| Half-life | 12-15 hours (R-enantiomer ~15h; S-enantiomer ~4-6h) |
| Peak plasma | 2-4 hours |
| Bioavailability | ~45-65% |
| Metabolism | Hepatic (CYP3A4/5); metabolites: modafinil acid, modafinil sulfone |
| Protein binding | ~60% (albumin) |
Swipe table →
Armodafinil (Nuvigil®)
| Property | Details |
|---|---|
| Structure | Pure R-enantiomer of modafinil |
| Advantage | Longer half-life; more sustained plasma levels; potentially fewer side effects |
| Duration | Up to 15+ hours of effect |
| FDA approval | 2007 (same indications as modafinil) |
Swipe table →
Adrafinil
| Property | Details |
|---|---|
| Structure | Prodrug of modafinil (converted in liver) |
| Availability | OTC in some countries; NOT FDA-approved |
| Disadvantages | Requires hepatic conversion (liver strain); less efficient; takes longer to act |
| Monitoring | Liver enzymes (ALT/AST) should be monitored with long-term use |
Swipe table →
Solriamfetol (Sunosi®)
| Property | Details |
|---|---|
| Mechanism | Dopamine and norepinephrine reuptake inhibitor (DNRI) |
| Approval | 2019 (narcolepsy, OSA) |
| Dose | — |
| Advantage | Potent wakefulness without anxiety (per comparative studies) |
| Note | Technically not a "true" eugeroic (different mechanism), but classified as wakefulness-promoting |
Swipe table →
04Mechanism of Action: A Drug in Search of a Mechanism
Modafinil has been famously described as "a drug in search of a mechanism" (Saper & Scammell, 2004). Decades of research have revealed a complex, multi-system profile that distinguishes it from classical stimulants.
Primary Mechanism: Atypical DAT Inhibition
Evidence Level: ⭐⭐⭐⭐ Very Strong
- Weak DAT affinity: Ki = 2.3 μM (vs. methylphenidate Ki = 0.02 μM — 100× stronger)
- High selectivity: Does not significantly bind to other receptors/transporters
- Atypical binding conformation: Binds DAT in an occluded/closed, inward-facing conformation (vs. cocaine's open, outward-facing conformation)
- Ceiling effect: Higher doses do NOT produce proportionally higher dopamine increases (unlike cocaine/amphetamine)
- Does NOT trigger the synapsin-dependent reserve pool release via CaMKII (unlike cocaine)
Why This Matters: This atypical binding explains modafinil's low abuse potential despite being a DAT inhibitor. It increases dopamine without the reward cascade that drives addiction.
Other Neurotransmitter Effects
| System | Effect | Brain Regions | Evidence Level |
|---|---|---|---|
| Serotonin (5-HT) | Indirectly increases in cortex, amygdala, dorsal raphe | Enhances serotonergic signaling | ⭐⭐⭐ Strong |
| GABA | Decreases in cortex, hypothalamus, nucleus accumbens, pallidum, striatum | Reduces inhibitory tone | ⭐⭐⭐ Strong |
| Glutamate | Increases in hypothalamus, hippocampus, thalamus | Excitatory enhancement | ⭐⭐⭐ Strong |
| Norepinephrine | Increases in hypothalamus, prefrontal cortex | Alertness, attention | ⭐⭐⭐ Strong |
| Orexin/Hypocretin | Activates orexin neurons | Wakefulness (but not essential — works without orexin) | ⭐⭐⭐ Strong |
| Histamine | Increases (indirect, via orexin) | Wakefulness | ⭐⭐⭐ Strong |
| BDNF | Increases brain-derived neurotrophic factor | Neuroprotective, plasticity | ⭐⭐ Moderate |
Swipe table →
Neuroprotective Properties
Evidence Level: ⭐⭐⭐ Strong
| Finding | Study |
|---|---|
| Increased cortical creatine-phosphocreatine pool | Pierard et al., 1995 |
| Protected against glutamate cytotoxicity | Antonelli et al., 1998 |
| Protected nigral neurons from MPTP damage (Parkinson's model) | Jenner et al., 2000 |
| Reduced oxidative damage: ↑ glutathione, ↓ malondialdehyde | Xiao et al., 2004 |
| Reduces neuroinflammation (unlike addictive stimulants which increase it) | Hersey & Tanda, 2023 (PMID 38467484) |
Swipe table →
EEG Profile
Unique among stimulants: - Decreases delta and theta power (like stimulants) - Increases alpha power (UNLIKE amphetamine, which decreases alpha) - Increases beta power (normalizing in narcoleptics) - Pattern consistent with improved brain efficiency, not simple stimulation
fMRI: Modulatory, Not Unilateral
- Increases cortical activation in subjects with low baseline activation
- Decreases cortical activation in subjects with high baseline activation
- Strong negative correlation (r = −0.74 to −0.76) between baseline and post-modafinil activation
- Contrasts with amphetamine, which simply increases cortical blood flow broadly
- Interpretation: Modafinil optimizes brain function rather than simply stimulating it
05Cognitive Enhancement Evidence
Meta-Analysis Results (Battleday & Brem, 2019)
19 placebo-controlled trials; 67 cognitive domain-specific effect sizes:
| Domain | Effect | Notes |
|---|---|---|
| Attention | Significant improvement | Most consistent finding |
| Executive function | Significant improvement | Planning, task-switching, inhibition |
| Learning/Memory | Significant improvement | Especially under high cognitive demand |
| Processing speed | Mixed | Less consistent enhancement |
Swipe table →
Task-Specific Effects
Enhanced by modafinil: - Sustained attention tasks (vigilance) - Pattern recognition - Spatial planning - Working memory under high load - Decision-making (reduced impulsivity) - Episodic memory (especially for emotionally neutral content)
NOT significantly enhanced: - Simple reaction time - Basic cognitive processing - Low-demand tasks (ceiling effects) - Creative thinking (may actually impair divergent thinking)
State-Dependent Effects
Modafinil's cognitive effects are largest when: - The individual is sleep-deprived (primary indication) - Task demands are high (complex, long-duration) - Baseline performance is lower (the modulatory fMRI finding) - The individual has ADHD or attention deficits
Less impressive when: - The individual is well-rested and high-performing - Tasks are simple or brief - Baseline performance is already optimal
06Side Effects and Safety
Common Side Effects (Usually Mild)
| Side Effect | Frequency | Severity |
|---|---|---|
| Headache | 10-34% | Mild-moderate |
| Nausea | 5-15% | Mild |
| Anxiety/nervousness | 5-10% | Mild-moderate |
| Insomnia | 5-10% | Dose/timing dependent |
| Dry mouth | 5-10% | Mild |
| Dizziness | 5-8% | Mild |
| GI upset | 5-8% | Mild |
Swipe table →
Serious but Rare
- Stevens-Johnson Syndrome (SJS): Very rare but potentially fatal skin reaction; more common in people with specific HLA alleles; requires immediate medical attention
- Psychiatric symptoms: Can exacerbate mania in bipolar disorder; rare psychotic episodes
- Cardiovascular: Generally safe but can increase heart rate and blood pressure in some; caution in cardiovascular disease
Drug Interactions
| Interaction | Mechanism | Significance |
|---|---|---|
| CYP3A4 substrates | Modafinil induces CYP3A4 | Reduces effectiveness of birth control, some statins, immunosuppressants |
| CYP2C19 substrates | Modafinil inhibits CYP2C19 | Increases levels of omeprazole, diazepam, phenytoin |
| Warfarin | Potential interaction | Monitor INR closely |
| MAOIs | Theoretical risk | Avoid combination |
| Caffeine | Additive stimulant effects | May increase anxiety/jitteriness |
| Alcohol | May mask alcohol effects | Caution advised |
Swipe table →
Tolerance and Dependence
- Tolerance: Generally does not develop to the wakefulness-promoting effects at therapeutic doses (unlike amphetamines)
- Dependence: Low risk; Schedule IV classification reflects this
- Withdrawal: Minimal withdrawal symptoms even after long-term use
- Abuse potential: Low — does not reliably maintain self-administration in animal models
07Off-Label and Investigational Uses
| Use | Evidence Level | Notes |
|---|---|---|
| ADHD | ⭐⭐⭐⭐ Strong | FDA initially considered approval; less effective than stimulants but preferred by some |
| Cognitive enhancement (healthy) | ⭐⭐⭐ Strong | Meta-analysis supports; state-dependent |
| Military operations | ⭐⭐⭐ Strong | Used by multiple militaries; helicopter pilot studies |
| Depression (adjunct) | ⭐⭐ Moderate | Studied for bipolar depression; fatigue in depression |
| Cocaine/methamphetamine addiction | ⭐⭐ Moderate | May reduce use/craving by providing non-addictive stimulation |
| Multiple sclerosis fatigue | ⭐⭐⭐ Strong | Significant improvement in fatigue scores |
| Cancer-related fatigue | ⭐⭐ Moderate | Some positive trials |
| Shift work disorder | ⭐⭐⭐⭐ Very Strong | FDA-approved indication |
Swipe table →
08Doses in studies
Therapeutic (Prescribed)
- Shift-work disorder: 200mg ~1 hour before shift
Cognitive Enhancement (Off-Label)
- Intermittent use: Many users report best results using modafinil 2-4 days per week rather than daily
- Timing: Take before 10 AM to avoid insomnia (12-15 hour half-life)
Harm Reduction
- Studies started low: 50-100mg to assess tolerance
- Reported cycles:: Use intermittently, not daily
- Hydrate: Modafinil is dehydrating
- Don't skip sleep: Modafinil masks sleepiness but doesn't replace sleep's restorative functions
- Monitor blood pressure: Especially in older users or those with cardiovascular risk
- Check interactions: Especially birth control (reduced effectiveness)
- Get bloodwork: Periodic liver function tests with long-term use
09Comparison with Other Stimulants
| Feature | Modafinil | Amphetamine | Methylphenidate | Caffeine |
|---|---|---|---|---|
| DAT affinity | Low (2.3 μM) | Moderate | High (0.02 μM) | Indirect |
| Mechanism | DAT inhibitor (atypical) | DAT/NET substrate + VMAT | DAT/NET blocker | Adenosine antagonist |
| Abuse potential | Low (Schedule IV) | High (Schedule II) | Moderate (Schedule II) | Low |
| Duration | 12-15 hours | 4-12 hours (depends on formulation) | 3-8 hours | 4-6 hours |
| Anxiety | Low-moderate | High | Moderate | Moderate |
| Neuroprotection | Yes | No (neurotoxic at high doses) | Mixed | Moderate |
| Cognitive effect | Attention, executive function | Broad stimulation + euphoria | Focus, attention | Alertness, mild cognitive boost |
Swipe table →
10Legal and Ethical Considerations
- United States: Schedule IV (prescription required); widely available through online pharmacies (gray market)
- United Kingdom: Prescription-only (POM)
- India: Available OTC in some pharmacies (Modalert, Modvigil brands)
- Military use: US Air Force approved for pilot fatigue (Go/No-Go pills protocol)
- Academic use: Survey data suggests 5-15% of university students have used cognitive enhancers
- Sports: Not banned by WADA (removed from prohibited list in 2005, then re-added in 2006; status varies)
Ethical Debate
- Fairness: Is cognitive enhancement "cheating"? Does it create unfair advantages?
- Coercion: If effective enhancers exist, will people be pressured to use them?
- Safety: Long-term effects of healthy people using modafinil are unknown
- Authenticity: Does enhancement diminish "authentic" achievement?
What studies and practitioners report
Amounts as reported in the cited sources: trial doses with the population studied, and practitioner-reported ranges marked as such. Not medical advice.
- Trial 100–400 mg/day · Modafinil, comparator arm adults with narcolepsy PMID 24107292
11Connections
12Sources
- PubMed 31433334PubMed 31433334
- Hersey M, Tanda G. "Modafinil, an atypical CNS stimulant?" Adv Pharmacol. 2023;98:65-112. PMID 38467484PubMed 38467484
- Battleday RM, Brem AK. "Modafinil for cognitive neuroenhancement in healthy non-sleep-deprived subjects: A systematic review." Eur Neuropsychopharmacol. 2015;25(11):1865-81. PMID 26320832PubMed 26320832
- Gerrard P, Malcolm R. "Mechanisms of modafinil: A review of current research." Neuropsychiatr Dis Treat. 2007;3(3):349-56. PMC2654794PMC2654794
- Turner DC, et al. "Modafinil improves cognition and response inhibition in adult ADHD." Biol Psychiatry. 2004;55(10):1031-40. PMID 15121488PubMed 15121488
- Willie JT, et al. "Modafinil more effectively induces wakefulness in orexin-null mice." J Neurosci. 2005;25(18):4488-96. PMID 15652995PubMed 15652995
- Kaser et al. 2017 ( PMC5339412 ): Double-blind RCT in remitted depression (n=60). Modafinil improved episodic memory and working memory vs. placebo after one week. Executive function unchanged.PMC5339412
- Earlier mixed evidence: some RCTs positive on working memory and attention; COMT Val/Val genotype subgroup analyses ( NCT00057707 ) suggest pharmacogenomic moderation of cognitive response.NCT00057707
13Entry history
Latest content update.
Heretic informs and never prescribes. Where amounts appear, they describe what published studies used. Talk to a qualified clinician before acting on anything here.